Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Jefferies has downgraded its rating on Novo Nordisk (NYSE:NVO) to "underperform" and cut its price target to DKK 575, down from the previous DKK 782.90. The downgrade comes amid concerns over the supply of the Danish drugs giant's weight-loss drug, Wegovy, particularly in the United States, where prescriptions for the 0.25 mg starter dose have dropped significantly.

Novo Nordisk downgraded amid supply bottlenecks

Eli Lilly

Regeneron Pharmaceuticals

Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications.

Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)

Visa

These companies have been on fire for a while, but they haven't peaked yet.

Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030

Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production globally, the firm said on Friday.

Novo Nordisk to invest $158 million in insulin plant in Brazil

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter.

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem.

Analysts from Citi are bullish about the GLP-1 market, particularly within obesity and diabetes treatments, signaling a positive outlook for key players despite facing some supply constraints. According to Citi, there was an impressive 244% increase in total prescriptions for obesity drugs, such as Wegovy, and an 18% rise for diabetes medications, including Ozempic and Rybelsus.

Wegovy and Ozempic drive impressive prescription growth, says Citi

Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.

Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years

ASML Hld

Infineon Technologies AG

U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated. Generally, a lower federal funds rate is often a boon for stocks, as businesses are able to more easily secure loans to facilitate growth and consumers may be more likely to increase spending habits.

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Pfizer

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?

PFE vs. NVO: Which Stock Is the Better Value Option?

Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.

Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales

It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs.

Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?

Evotec SE

On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?

Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.

Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.

Evotec and Novo Nordisk forge technology development partnership

Some experts believe Novo Nordisk A/S  NVO products not only help people lose weight and control diabetes, they can help treat the country's addiction crisis.

Lose Weight With Novo Nordisk Drugs, Gain Money With Stock

Novo Nordisk's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study. The results suggest semaglutide, the active ingredient in Ozempic, could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.

Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says

Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.

Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.

Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next

Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result.

Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges

The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.

Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill

Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen, will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m.

Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices

U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,000 a month.

Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing

Amgen

Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.

News for Novo Nordisk Stock (NVO)